Patients Stopping Slimming Medications Regain Weight Far More Rapidly Than Those on Conventional Diets

New research indicates that people who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who end conventional diet and exercise plans.

Research printed in a major medical journal demonstrates that while obese people can lose substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.

"People purchasing such drugs should be informed of the risk of fast weight regain when the treatment is stopped," warns expert Dr. Susan Jebb.

Such speed of regain means a reversion to starting weight in about one and a half years.

Comparing Treatments

The study, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.

Scientists point out that individuals who shed pounds through diet and exercise typically see a slower creep back—around 0.1 kg a month—once they finish.

Understanding the Quick Regain

Nutrition scientists suggest the mechanism of the injections accounts for the amplified regain.

The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.

"Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making overeating a significant risk."

A Chronic Disease?

The NHS recommend the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.

Many experts contend that, due to the significant potential of weight regain, the treatment is often long-term.

This view is supported by drug manufacturers, who note that the findings "emphasize the persistent nature of obesity," comparing it to managing conditions like high blood pressure.

Patient Testimonies

People who have stopped the medication describe a powerful return of cravings.

"It was like a trigger activating and you're instantly ravenous," recalled an individual.

This challenge is compounded if patients have not adopted lasting dietary or behavioural changes during therapy.

Significant Interest

Figures suggest that millions of adults in the UK have tried these injections in the past year, with interest being substantial.

• Use is higher among females compared to males.
• The 40s and 50s demographic shows the greatest usage rates.
• Many obtain the medications through private prescriptions rather than public health services.

In conclusion, clinicians caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural support.